JP7128191B2 - 治療抗ＩｇＥ抗体並びにその方法及び組成物 - Google Patents

治療抗ＩｇＥ抗体並びにその方法及び組成物 Download PDF

Info

Publication number
JP7128191B2
JP7128191B2 JP2019537154A JP2019537154A JP7128191B2 JP 7128191 B2 JP7128191 B2 JP 7128191B2 JP 2019537154 A JP2019537154 A JP 2019537154A JP 2019537154 A JP2019537154 A JP 2019537154A JP 7128191 B2 JP7128191 B2 JP 7128191B2
Authority
JP
Japan
Prior art keywords
seq
ige
hlaaige
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505334A (ja
JP2020505334A5 (enExample
Inventor
サクソン，アンドリュー
チャン，ケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7128191(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020505334A publication Critical patent/JP2020505334A/ja
Publication of JP2020505334A5 publication Critical patent/JP2020505334A5/ja
Priority to JP2022130651A priority Critical patent/JP7461420B2/ja
Application granted granted Critical
Publication of JP7128191B2 publication Critical patent/JP7128191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019537154A 2017-01-06 2018-01-05 治療抗ＩｇＥ抗体並びにその方法及び組成物 Active JP7128191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130651A JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130651A Division JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020505334A JP2020505334A (ja) 2020-02-20
JP2020505334A5 JP2020505334A5 (enExample) 2021-02-04
JP7128191B2 true JP7128191B2 (ja) 2022-08-30

Family

ID=62789396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537154A Active JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗ＩｇＥ抗体並びにその方法及び組成物
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Country Status (6)

Country Link
US (2) US11518818B2 (enExample)
EP (1) EP3565587A4 (enExample)
JP (2) JP7128191B2 (enExample)
AU (1) AU2018205484B2 (enExample)
CA (1) CA3049967C (enExample)
WO (1) WO2018129248A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051507A1 (fr) 2000-01-14 2001-07-19 Daiichi Pharmaceutical Co., Ltd. Nouveau peptide et procede de criblage utilisant ledit peptide
JP2006516408A (ja) 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法
JP2008507474A (ja) 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定
WO2015195631A1 (en) 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
EP2511299A1 (en) * 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051507A1 (fr) 2000-01-14 2001-07-19 Daiichi Pharmaceutical Co., Ltd. Nouveau peptide et procede de criblage utilisant ledit peptide
JP2006516408A (ja) 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法
JP2008507474A (ja) 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定
WO2015195631A1 (en) 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS

Also Published As

Publication number Publication date
US20230090487A1 (en) 2023-03-23
JP7461420B2 (ja) 2024-04-03
US11518818B2 (en) 2022-12-06
WO2018129248A1 (en) 2018-07-12
CA3049967C (en) 2024-10-01
JP2022172170A (ja) 2022-11-15
US20190322766A1 (en) 2019-10-24
CA3049967A1 (en) 2018-07-12
AU2018205484B2 (en) 2024-11-21
EP3565587A1 (en) 2019-11-13
EP3565587A4 (en) 2020-12-16
AU2018205484A1 (en) 2019-08-01
JP2020505334A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
US10336831B2 (en) Use of anti-endoglin antibodies for treating ocular fibrosis
JP6963036B2 (ja) Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
CN106794129B (zh) 对il-21具有特异性的结合分子及其用途
CA3067747A1 (en) Anti-allergen antibodies
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
JP7667773B2 (ja) カンジダ属に対する抗体およびその使用法
CN104603150A (zh) 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
JP7461420B2 (ja) 治療抗ＩｇＥ抗体並びにその方法及び組成物
JP2022172170A5 (enExample)
JP2021533806A (ja) 抗ｆｃイプシロン−ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
US20200115439A1 (en) HUMAN IgE ANTIBODIES BINDING TO ASPERGILLUS ALLERGENS
EP4259180A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
JP7754841B2 (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
TW202413405A (zh) 抗體、其抗原結合片段及其藥物用途
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220818

R150 Certificate of patent or registration of utility model

Ref document number: 7128191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250